Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Net Cash Flow (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Net Cash Flow for 16 consecutive years, with -$25.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 48.67% year-over-year to -$25.0 million, compared with a TTM value of $148.0 million through Dec 2025, up 1862.31%, and an annual FY2025 reading of $124.3 million, up 1101.89% over the prior year.
  • Net Cash Flow was -$25.0 million for Q4 2025 at Arrowhead Pharmaceuticals, down from $96.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $232.5 million in Q1 2021 and bottomed at -$141.5 million in Q3 2021.
  • Average Net Cash Flow over 5 years is $2.9 million, with a median of -$27.3 million recorded in 2023.
  • The sharpest move saw Net Cash Flow plummeted 2434.35% in 2021, then soared 435.71% in 2024.
  • Year by year, Net Cash Flow stood at -$92.8 million in 2021, then soared by 201.68% to $94.4 million in 2022, then plummeted by 155.88% to -$52.7 million in 2023, then rose by 7.6% to -$48.7 million in 2024, then surged by 48.67% to -$25.0 million in 2025.
  • Business Quant data shows Net Cash Flow for ARWR at -$25.0 million in Q4 2025, $96.8 million in Q3 2025, and -$56.0 million in Q2 2025.